Login / Signup

Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.

Johann-Christoph JannChristopher B HergottMarisa WinklerYiwen LiuBenjamin BraunAnne CharlesKevin M CopsonShougat BaruaManja MeggendorferNiroshan NadarajahShai ShimonyEric S WinerMartha WadleighRichard M StoneDaniel J DeAngeloJacqueline S GarciaTorsten HaferlachR Coleman LindsleyMarlise R LuskinMaximilian StahlZuzana Tothova
Published in: Leukemia (2024)
Mutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit mutations share clinical characteristics and prognostic significance is not known. We analyzed 790 cohesin-mutant patients from the Dana-Farber Cancer Institute (DFCI) and the Munich Leukemia Laboratory (MLL), 390 of which had available outcome data, and identified subunit-specific clinical, prognostic, and genetic characteristics suggestive of distinct ontogenies. We found that STAG2 mutations are acquired at MDS stage and are associated with secondary AML, adverse prognosis, and co-occurrence of secondary AML-type mutations. In contrast, mutations in RAD21, SMC1A and SMC3 share features with de novo AML with better prognosis, and co-occurrence with de novo AML-type lesions. The findings show the heterogeneous nature of cohesin complex mutations, and inform clinical and prognostic classification, as well as distinct biology of the cohesin complex.
Keyphrases